Sudeep Pharma Limited reported a 30% year-on-year increase in consolidated net profit to ₹4,058.69 lakhs for the quarter ended June 30, 2026, signaling robust operational momentum following its November 2025 listing. Consolidated revenue from operations rose 26.7% to ₹15,827.05 lakhs, primarily driven by the pharmaceutical, food, and nutrition segment which contributed ₹10,841.37 lakhs. The company’s Board of Directors approved the unaudited standalone and consolidated financial results on August 4, 2026, in compliance with Regulation 30(6) of the SEBI Listing Regulations, 2015.

The statutory auditor, B S R and Co, conducted a limited review of the results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The review covered the group’s financial statements prepared under Indian Accounting Standard 34 (Ind AS 34). B S R and Co noted that the figures for the three months ended March 31, 2026, are balancing figures between audited full-year data and published year-to-date figures up to the third quarter.

Financial Performance

Consolidated total income reached ₹16,371.59 lakhs, up from ₹13,007.60 lakhs in the corresponding quarter of the previous year. Other income stood at ₹544.54 lakhs. Total expenses were ₹10,942.33 lakhs, with cost of materials consumed at ₹6,880.57 lakhs and employee benefits expense at ₹1,433.97 lakhs. Profit before tax was ₹5,429.26 lakhs, compared to ₹4,407.20 lakhs in Q1FY25.

Standalone net profit rose 34.2% to ₹3,382.85 lakhs from ₹2,520.49 lakhs in the prior year period. Standalone revenue from operations increased 31.8% to ₹10,568.33 lakhs. Earnings per share (basic) were ₹3.59 on a consolidated basis and ₹3.00 on a standalone basis.

Segment Analysis

The group operates in two segments: pharmaceutical, food, and nutrition; and speciality ingredients. The pharmaceutical, food, and nutrition segment generated external revenues of ₹10,841.37 lakhs, a significant increase from ₹8,298.68 lakhs in Q1FY25. Its segment result before other income, finance costs, and tax was ₹4,185.79 lakhs. The speciality ingredients segment reported external revenues of ₹4,985.68 lakhs, up from ₹4,193.07 lakhs, with a segment result of ₹1,305.34 lakhs.

IPO Proceeds Utilisation

The company listed its equity shares on the National Stock Exchange and Bombay Stock Exchange on November 28, 2025, receiving net proceeds of ₹8,833.59 lakhs after deducting estimated offer-related expenses of ₹666.41 lakhs borne by the company. As of June 30, 2026, ₹1,287.96 lakhs had been utilized, with ₹1,252.19 lakhs deployed for general corporate purposes and ₹35.77 lakhs towards capital expenditure for machinery procurement at the Nandesari Facility I. The remaining unutilised proceeds of ₹7,545.63 lakhs are held as term deposits in banks.

What the Numbers Show

The divergence between revenue growth (26.7%) and expense growth (27.5%) indicates slight operating leverage pressure, though overall profitability expanded due to higher absolute margins. The pharmaceutical, food, and nutrition segment continues to be the primary profit driver, contributing approximately 82% of the total segment result before tax, while the speciality ingredients segment saw a decline in its absolute result despite revenue growth, suggesting potential margin compression or higher specific costs in that division.

Sudeep Pharma Limited shareholders adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, during the company’s 37th Annual General Meeting held on August 4, 2026. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM), served as the primary forum for approving the company’s strategic pivot into advanced battery materials alongside its core pharmaceutical and nutrition business. The adoption of these results confirms the company’s highest-ever revenue from operations of ₹642 crore, underpinned by a 63% surge in its Specialty Ingredients segment.

The proceedings were held in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dimple Mehta, Company Secretary & Compliance Officer, confirmed that the requisite quorum was present. The statutory auditors, B S R and Co., Chartered Accountants, and secretarial auditors, H M Mehta & Associates, were present. Mr. Hemang Mehta of H M Mehta & Associates was appointed as the scrutinizer for the e-voting process. The voting facility remained open until 11:42 a.m. IST, following the conclusion of the meeting at 11:27 a.m. IST.

Financial Performance and Segment Growth

Management highlighted that FY26 was a landmark year characterized by disciplined execution and significant capacity expansion. Revenue from operations reached ₹642.3 crore, driven largely by the Specialty Ingredients segment, which grew by 63% to ₹280 crore. This segment now accounts for approximately 44% of total revenue, up from 34% in the previous year. The Pharmaceutical, Food and Nutrition business contributed ₹362 crore, representing 56% of total revenue, with growth constrained by optimal utilization of existing facilities.

Exports remained a core strength, contributing approximately 60% of total revenue. The company maintained a strong balance sheet with net debt of ₹33.6 crore and a net debt-to-equity ratio of just 0.04. Management noted that return ratios moderated due to investments in new capacity, the integration of NSS in Ireland, and the deployment of IPO proceeds.

Strategic Expansion into Advanced Materials

A key focus of the AGM was the company’s entry into the electric vehicle and energy storage ecosystem through Sudeep Advanced Materials. Leveraging over a decade of expertise in iron phosphate chemistry for nutrition applications, the company is applying this science to battery-grade materials. Construction of the Phase I facility at Dahej is progressing as planned, with an annual capacity of 25,000 metric tonnes and commissioning targeted for April 2027.

The company reported engaging with 42 global customers across the EV, battery cell, cathode material, and energy storage sectors. Several customers are advancing through laboratory validation and pilot evaluation, resulting in initial commercial orders of approximately 700 metric tonnes. To serve early demand ahead of the Dahej commissioning, Sudeep Pharma upgraded an existing line to manufacture battery-grade material. This diversification aims to create multiple engines of growth beyond traditional mineral-based ingredients.

Governance and Board Appointments

Shareholders approved several special resolutions to support long-term governance and growth strategies. The assembly ratified the remuneration for Cost Auditors for FY27 and appointed Mr. Hemang Mehta as Secretarial Auditor for a term of five consecutive years. Mr. Milin Mehta was appointed as a Non-Executive, Non-Independent Director. Additionally, shareholders approved the re-appointment of Mr. Ajay Shrirang Kandelkar as a director retiring by rotation and approved a change in his remuneration as Whole Time Director effective April 1, 2026.

The meeting also saw the ratification of the 'Sudeep Pharma Employee Stock Option Scheme 2025' and the approval to grant options to eligible employees of subsidiary and group companies. A new set of Articles of Association was adopted to align with evolving corporate requirements. There were no qualifications or adverse remarks in the Statutory Auditor’s Report or the Secretarial Audit Report, indicating clean compliance across all audited areas.